Kimberly Clark Corp

Company facts

Industry

Converted Paper & Paperboard Prods (No Contaners/Boxes)

Headquarters

Irving, Texas

Most recent report

10-Q, filed Nov 5, 2026

Incorporated

Delaware

Filings on record

1,002+ filings

On EDGAR

CIK 55785

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 9 sections worth reading, with 0 positive, 10 notable, and 5 negative flags.

• Financial Statements (Item 1)

  Major events: IFP sale closed, Kenvue acquisition completed post-period, $4.9B debt issued.
  Notable

  • IFP sale closed July 1, 2026: $1.3B cash proceeds, $1.4B pre-tax gain, retained 49% equity stake.
  • 2024 Transformation Initiative extended through 2028; total pre-tax costs now ~$1.5B, $968 cumulative through Q3 2026.
  • Kenvue acquisition completed Nov 2, 2026: ~$6.7B cash + 281.1M shares issued; funded by $4.9B notes and $1.0B CP.
  • Entered $4.3B forward-starting interest rate swaps in Q2 2026; settled post-period for Kenvue debt issuance.
  • Supplier finance program outstanding fell to $836M at Sep 30, 2026 from $1.1B at Dec 31, 2025.
  • Board approved $3.1B Kenvue Integration Program on Oct 30, 2026, expected to run through 2029.

• Management's Discussion (Item 2)

  Major acquisition closed, China disruption quantified, IFP sale gain, and segment results diverge sharply.
  Notable

  • 2024 Transformation Initiative extended through 2028; cumulative pre-tax charges $968M through Sep 30, 2026.
  • Adjusted EPS from continuing ops rose 17.2% to $1.70 in Q3 2026, aided by lower tax rate (19.5% vs 26.5%) and lower interest.
  • No share repurchases in nine months ended Sep 30, 2026; total debt from continuing ops was $6.5B, down from $7.2B at Dec 2025.
  Negative

  • China diaper social-media disruption caused ~270 bps Q3 volume headwind; IPC organic sales fell 4.6% in Q3 2026.
  • IPC operating profit fell 32.7% in Q3 2026 ($144M vs $214M), hit by China disruption (~16.8% headwind) and input costs.

• Risk Factors (Item 1A)

  New Kenvue acquisition risks: integration, debt, product safety, J&J dependency, and talc exposure.
  Notable

  • Integration of Kenvue's systems is complex, costly, and could disrupt operations or financial reporting.
  Negative

  • Acquisition added significant debt and shares, reducing financial flexibility for investments and dividends.
  • FDA proposed removing oral PE from OTC monograph in Nov 2024, could force reformulation of Sudafed PE and Tylenol Cold & Flu.
  • Kenvue indemnifies J&J for Zantac and PE securities claims; J&J's talc indemnity may be insufficient and excludes non-US/Canada.

What changed: Sep 2026 vs. Jun 2026

About 20% of KMB's Sep 2026 10-Q is new information. 59 paragraphs were added, 107 changed, and 53 removed. Below are the most important lines SECSift identified.

• Item 1 57
• Item 2 49
• Item 1A 18
• Item 6 1
• Item 4 1
• Item 5 1